ArticleBreast cancer research : BCR2025

ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy.

Konstantinos Venetis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.